TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10683000

Group type: EXPERIMENTAL
Intervention: Folic acid (5 mg) plus vitamin B6 (250 mg) daily for 2 years
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study: 10183187

Group type: EXPERIMENTAL
Intervention: Intervention 1 (specific details not available)
Number of subjects: 1278

Group type: EXPERIMENTAL
Intervention: Intervention 2 (specific details not available)
Number of subjects: 1278

Group type: COMPARATOR
Intervention: Control group (specific details not available)
Number of subjects: 1278
Study: 8372519

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cold saline organ perfusion
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 24
Study: 3528273

Group type: EXPERIMENTAL
Intervention: Gentle touch during eating
Number of subjects: 42

Group type: COMPARATOR
Intervention: Verbal encouragement
Number of subjects: 42
Study: 3335080

Group type: EXPERIMENTAL
Intervention: Vinblastine (VLB) 6 mg/m2 weekly intravenous bolus injection
Number of subjects: 50

Group type: COMPARATOR
Intervention: Locoregional radiotherapy (RT) alone
Number of subjects: 50
Study: 31551155

Group type: EXPERIMENTAL
Intervention: PGT-A (n = 330)
Number of subjects: 661

Group type: COMPARATOR
Intervention: Morphology alone (n = 331)
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: PGT-A in women aged 35-40 years
Number of subjects: 661
Study: 28919201

Group type: EXPERIMENTAL
Intervention: Macitentan (10 mg once a day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Macitentan
Number of subjects: 80
Study: 25976467

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (n-3) supplementation (277.8 mg DHA and 39.0 mg EPA)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (n-3) supplementation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Hydroxyurea (HU) treatment (dosage > 20 mg/kg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: n-3 untreated
Number of subjects: 24
Study: 23035747

Group type: EXPERIMENTAL
Intervention: Plasma vaporization
Number of subjects: 65

Group type: COMPARATOR
Intervention: Balloon dilatation
Number of subjects: 65
Study: 21741428

Group type: EXPERIMENTAL
Intervention: Laser irradiation (CO(2) laser at 0.3J/cm(2), 0.5μs, 226Hz)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fluoride (AmF/NaF gel) application
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Laser prior to fluoride (LF)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fluoride prior to laser (FL)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-treated control (C)
Number of subjects: 60
Study: 18979086

Group type: EXPERIMENTAL
Intervention: 25-g glucose drink
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 16402081

Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 363
Study: 14580053

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.25%
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ropivacaine 0.25%
Number of subjects: 60
Study: 11032203

Group type: EXPERIMENTAL
Intervention: Patient-centered communication
Number of subjects: 315
Study: 9345021

Group type: EXPERIMENTAL
Intervention: Aerobic exercise program (biking on an ergometer in the supine position for 30 minutes daily during hospitalization)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Aerobic exercise program
Number of subjects: 33
Study: 8398218

Group type: EXPERIMENTAL
Intervention: Dietary fiber intake (continuous variable)
Number of subjects: 1801

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 1801
Study: 2427844

Group type: EXPERIMENTAL
Intervention: Celiprolol 200 mg daily for 2 weeks, then 400 mg daily for 2 weeks, and if necessary 600 mg daily for another 2 weeks.
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 31852268

Group type: EXPERIMENTAL
Intervention: bDMARDs (biologic disease-modifying anti-rheumatic drugs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: csDMARDs (conventional synthetic disease-modifying anti-rheumatic drugs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: bDMARDs (specifically rituximab)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TNF inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: cyclosporine and TNF inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rituximab
Number of subjects: 0
Study: 27856142

Group type: EXPERIMENTAL
Intervention: Onartuzumab (15 mg/kg intravenously every 3 weeks) in combination with bevacizumab-based chemotherapy
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Onartuzumab (15 mg/kg intravenously every 3 weeks) in combination with pemetrexed-based chemotherapy
Number of subjects: 259

Group type: COMPARATOR
Intervention: Placebo in combination with bevacizumab-based chemotherapy
Number of subjects: 259

Group type: COMPARATOR
Intervention: Placebo in combination with pemetrexed-based chemotherapy
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Onartuzumab
Number of subjects: 259
Study: 26214269

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 140
Study: 24393344

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) in addition to standard wound care (5 sessions per week for 8 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard wound care (5 sessions per week for 8 weeks)
Number of subjects: 0
Study: 22366196

Group type: EXPERIMENTAL
Intervention: Aclidinium 200 μg, 400 μg, 800 μg, twice daily for 7 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Aclidinium 400 μg, twice daily for 7 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Aclidinium 800 μg, twice daily for 7 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Aclidinium (all doses), twice daily for 7 days
Number of subjects: 30
Study: 18979100

Group type: EXPERIMENTAL
Intervention: Combined intra-arterial chemotherapy
Number of subjects: 53
Study: 17263651

Group type: EXPERIMENTAL
Intervention: Contingency management (CM) based counseling
Number of subjects: 56

Group type: COMPARATOR
Intervention: Supportive counseling
Number of subjects: 56
Study: 14871511

Group type: EXPERIMENTAL
Intervention: Tocolysis with ritodrine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no tocolysis)
Number of subjects: 60
Study: 11880016

Group type: EXPERIMENTAL
Intervention: 10% lidocaine sprayed on the distal end of the endotracheal tubes (ETTs)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: 10% lidocaine sprayed on laryngopharyngeal structures
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: 2% lidocaine jelly lubricated on distal ends of ETTs
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) lidocaine administered at the conclusion of surgery
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Intracuff lidocaine
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Normal saline lubricated on terminal end of ETTs
Number of subjects: 204
Study: 10726810

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 7587896

Group type: EXPERIMENTAL
Intervention: Furlutal (group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Furlutal (group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Furlutal (group C)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Chemotherapy only (control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus Furlutal
Number of subjects: 60
Study: 2339013

Group type: EXPERIMENTAL
Intervention: Amitriptyline + psychotherapy (N = 26), twelve 45 min weekly sessions
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Amitriptyline + support (N = 26), six 15 min fortnightly sessions
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo tablet + psychotherapy (N = 26), twelve 45 min weekly sessions
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo tablet + support (N = 24), six 15 min fortnightly sessions
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Amitriptyline + psychotherapy (N = 26)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Amitriptyline (general)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Psychotherapy (general)
Number of subjects: 102
Study: 7006811

Group type: EXPERIMENTAL
Intervention: Aldoretic (methyldopa, hydrochlorothiazide, and amiloride)
Number of subjects: 361

Group type: COMPARATOR
Intervention: Hydrochlorothiazide and amiloride
Number of subjects: 361

Group type: COMPARATOR
Intervention: Methyldopa alone
Number of subjects: 361
Study: 31358922

Group type: EXPERIMENTAL
Intervention: Intravitreal Conbercept injections (three loading doses and thereafter pro re nata [PRN])
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (3 months' sham injection, then one Conbercept injection at month 4 and thereafter PRN)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Overall incidence of MRS
Number of subjects: 160
Study: 30712901

Group type: EXPERIMENTAL
Intervention: PICSI
Number of subjects: 2772

Group type: COMPARATOR
Intervention: ICSI
Number of subjects: 2772
Study: 28470919

Group type: EXPERIMENTAL
Intervention: Early implantation of veno‐arterial ECMO on the background of standard care
Number of subjects: 120

Group type: COMPARATOR
Intervention: Early conservative therapy
Number of subjects: 120
Study: 27111542

Group type: EXPERIMENTAL
Intervention: CBT for GAD
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CBT for insomnia
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CBT for GAD followed by CBT for insomnia
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CBT for insomnia following CBT for GAD
Number of subjects: 10
Study: 24418670

Group type: EXPERIMENTAL
Intervention: Clinical read with prior images
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Laboratory read with prior images
Number of subjects: 10

Group type: COMPARATOR
Intervention: Laboratory read without prior images
Number of subjects: 10
Study: 22528672

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound (EUS)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: EUS
Number of subjects: 123
Study: 19033321

Group type: EXPERIMENTAL
Intervention: Ulinastatin plus Thymosin alpha(1)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 17381962

Group type: EXPERIMENTAL
Intervention: 5 g carob fibre
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 10 g carob fibre
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0 g carob fibre (control)
Number of subjects: 20
Study: 15620164

Group type: EXPERIMENTAL
Intervention: 1% propofol (Propofol‐Lipuro 1%, B. Braun, Melsungen, Germany) in a 10% fat emulsion containing equal proportions (50:50) of medium‐ and long‐chain triglycerides
Number of subjects: 600
Study: 11719888

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (0.075 g x kg(‐1) body mass, 4 times daily for 5 days)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (maltodextrine, 4 times daily for 5 days)
Number of subjects: 9
Study: 9533108

Group type: EXPERIMENTAL
Intervention: phenytoin + tirilazad
Number of subjects: 12
Study: 7989879

Group type: EXPERIMENTAL
Intervention: Treatment group 1: diversified spinal manipulation, drop table adjustments, and cervical extension-compression traction five times per week for 10-14 weeks.
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Treatment group 2: diversified spinal manipulation and drop table adjustments five times per week for 10-14 weeks.
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group: no health care for 10-14 weeks.
Number of subjects: 95
Study: 2465530

Group type: EXPERIMENTAL
Intervention: Amitriptyline (75 mg/day)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Carbamazepine (800 mg/day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31634011

Group type: EXPERIMENTAL
Intervention: Technology-enabled clinical trials using electronic health records, mobile applications, and wearable devices
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 29102818

Group type: EXPERIMENTAL
Intervention: Paroxetine, 12 weeks of open treatment
Number of subjects: 138
Study: 26736632

Group type: EXPERIMENTAL
Intervention: 30 min real LTE EMF exposure at 2.573 GHz
Number of subjects: 0

Group type: COMPARATOR
Intervention: 30 min sham LTE EMF exposure
Number of subjects: 0
Study: 23411523

Group type: EXPERIMENTAL
Intervention: Maxillary protraction with double hinged expander repetitive rapid palatal expansions/constrictions (group B)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Maxillary protraction with Hyrax expander rapid palatal expansion alone (group A)
Number of subjects: 34
Study: 21985070

Group type: EXPERIMENTAL
Intervention: Prasugrel 10 mg day(-1)
Number of subjects: 21

Group type: COMPARATOR
Intervention: High-dose clopidogrel 150 mg day(-1)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 21

Group type: COMPARATOR
Intervention: High-dose clopidogrel
Number of subjects: 21
Study: 19834053

Group type: EXPERIMENTAL
Intervention: Familias Unidas
Number of subjects: 213

Group type: COMPARATOR
Intervention: Community Control
Number of subjects: 213
Study: 17107539

Group type: EXPERIMENTAL
Intervention: Endo IT motor
Number of subjects: 60

Group type: COMPARATOR
Intervention: Mtwo direct handpiece
Number of subjects: 60
Study: 15515816

Group type: EXPERIMENTAL
Intervention: ccHRT (50 mg of 17beta‐estradiol and 5 mg of oral progesterone)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no ccHRT)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: ccHRT
Number of subjects: 34
Study: 11273923

Group type: EXPERIMENTAL
Intervention: Rectal acetaminophen 10 mg/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Rectal acetaminophen 20 mg/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Rectal acetaminophen 40 mg/kg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: IV opioid boluses (piritramide)
Number of subjects: 80
Study: 9058127

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery (laparoscopic colectomy)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Advanced colorectal cancer treatment
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Lymph node metastasis in early colorectal cancer
Number of subjects: 90

Group type: COMPARATOR
Intervention: Comparison of clinicopathologic features
Number of subjects: 90
Study: 7643049

Group type: EXPERIMENTAL
Intervention: Detection of simple quadratic surfaces with 4-6 points
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Detection of hyperbolic shapes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Detection of sinusoidal shapes
Number of subjects: 0
Study: 2495913

Group type: EXPERIMENTAL
Intervention: recombinant human tissue‐type plasminogen activator (rtPA)
Number of subjects: 0
Study: 645630

Group type: EXPERIMENTAL
Intervention: Potassium supplementation (4.3, 98.0, and 0.0 mEq/liter of potassium) given 1 to 2 hr before physical activity
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Potassium supplementation (98.0 mEq/liter)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Total body potassium measurement before and after exercise
Number of subjects: 5
Study: 30658660

Group type: EXPERIMENTAL
Intervention: BMF (Chinese herbal medicine bi min fang)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Levocetirizine hydrochloride (control)
Number of subjects: 80
Study: 28216328

Group type: EXPERIMENTAL
Intervention: 5α‐reductase inhibitors
Number of subjects: 78815

Group type: COMPARATOR
Intervention: Screening
Number of subjects: 78815

Group type: COMPARATOR
Intervention: Prostate specific antigen and age
Number of subjects: 78815
Study: 27618925

Group type: EXPERIMENTAL
Intervention: 800 mg of penicillin V four times daily for 5 days
Number of subjects: 432

Group type: COMPARATOR
Intervention: 1000 mg of penicillin V three times daily for 10 days
Number of subjects: 432
Study: 23820706

Group type: EXPERIMENTAL
Intervention: Large particle size of anorganic bovine bone matrix (ABBM)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Small particle size of anorganic bovine bone matrix (ABBM)
Number of subjects: 13
Study: 22262336

Group type: EXPERIMENTAL
Intervention: Transfixation screw (tricortical or quadricortical syndesmotic screw)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Reabsorbable cerclage (tibiofibular cerclage with reabsorbing wires)
Number of subjects: 30
Study: 19835718

Group type: EXPERIMENTAL
Intervention: Drospirenone 3 mg/ethinyl estradiol 20 mcg (drsp 3 mg/EE 20 mcg)
Number of subjects: 453

Group type: COMPARATOR
Intervention: Desogestrel 150 mcg/ethinyl estradiol 20 mcg (DSG 150 mcg/EE 20 mcg)
Number of subjects: 453
Study: 16711173

Group type: EXPERIMENTAL
Intervention: Sustained silver-releasing foam dressing Contreet Foam (ColoplastA/S)
Number of subjects: 619

Group type: COMPARATOR
Intervention: Local best practice (LBP)
Number of subjects: 619
Study: 14998051

Group type: EXPERIMENTAL
Intervention: Experimental power toothbrush (twice a day brushing with Crest Cavity Protection dentifrice for 2 minutes each time)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Peroxide paint-on gel control (Colgate Simply White Night applied once a day for the first 14 days, plus brushing twice a day with Crest Cavity Protection dentifrice for 2 minutes using ADA manual reference toothbrush)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Experimental power toothbrush (in induced stain study)
Number of subjects: 27
Study: 11708574

Group type: EXPERIMENTAL
Intervention: Policosanol 20 mg/day
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Policosanol 40 mg/day
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 8780541

Group type: EXPERIMENTAL
Intervention: Radiation
Number of subjects: 0
Study: 1882907

Group type: EXPERIMENTAL
Intervention: Sucralfate 2 g b.i.d.
Number of subjects: 52

Group type: COMPARATOR
Intervention: Sucralfate 1 g q.i.d.
Number of subjects: 52
Study: 6882613

Group type: EXPERIMENTAL
Intervention: fentanyl 2 micrograms kg‐1
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: alcuronium 0.03 mg kg‐1
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: fentanyl 1 microgram kg‐1
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: tubocurarine 0.06 mg kg‐1
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: pancuronium 0.01 mg kg‐1
Number of subjects: 171

Group type: COMPARATOR
Intervention: control group
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: pancuronium
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: tubocurarine
Number of subjects: 171
Study: 31812110

Group type: EXPERIMENTAL
Intervention: s-adenosyl methionine (MSI-195)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30688979

Group type: EXPERIMENTAL
Intervention: Intensive treatment group (systolic blood pressure goal < 120 mm Hg; n = 4678)
Number of subjects: 9361

Group type: COMPARATOR
Intervention: Standard treatment group (systolic blood pressure goal < 140 mm Hg; n = 4683)
Number of subjects: 9361

Group type: EXPERIMENTAL
Intervention: Intensive treatment group
Number of subjects: 9361

Group type: COMPARATOR
Intervention: Standard treatment group
Number of subjects: 9361
Study: 28617764

Group type: EXPERIMENTAL
Intervention: Oropharyngeal administration of 0.2 mL of mother's colostrum every 4 hours for 7 days
Number of subjects: 64

Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Oropharyngeal administration of colostrum
Number of subjects: 64
Study: 27703563

Group type: EXPERIMENTAL
Intervention: Automated oscillometric blood pressure device (Dinamap Procare 100)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Manual mercury sphygmomanometer
Number of subjects: 200
Study: 24422892

Group type: EXPERIMENTAL
Intervention: Secondary cytoreductive surgery followed by at least six cycles of intravenous platinum-based chemotherapy
Number of subjects: 230

Group type: COMPARATOR
Intervention: At least six cycles of intravenous platinum-based chemotherapy
Number of subjects: 230
Study: 26557330

Group type: EXPERIMENTAL
Intervention: LiSN & Learn auditory training program
Number of subjects: 10

Group type: COMPARATOR
Intervention: Earobics auditory training program
Number of subjects: 10
Study: 19269520

Group type: EXPERIMENTAL
Intervention: Short-course preoperative radiotherapy
Number of subjects: 1156

Group type: EXPERIMENTAL
Intervention: Circumferential resection margin negative
Number of subjects: 1156

Group type: EXPERIMENTAL
Intervention: Circumferential resection margin positive
Number of subjects: 1156

Group type: EXPERIMENTAL
Intervention: Plane of surgery achieved - mesorectal
Number of subjects: 1156

Group type: EXPERIMENTAL
Intervention: Plane of surgery achieved - intramesorectal
Number of subjects: 1156

Group type: EXPERIMENTAL
Intervention: Plane of surgery achieved - muscularis propria
Number of subjects: 1156
Study: 17898947

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) therapy for detoxification, removing stasis, and nourishing yin, in addition to prednisone, for 6 months.
Number of subjects: 170

Group type: COMPARATOR
Intervention: Western medicine group (WM group) treated with prednisone for 6 months.
Number of subjects: 170

Group type: COMPARATOR
Intervention: Follow-up study in IM group (25 patients) and WM group (16 patients).
Number of subjects: 170
Study: 15180973

Group type: EXPERIMENTAL
Intervention: Epinephrine infusion
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 8
Study: 12195686

Group type: EXPERIMENTAL
Intervention: Ramipril 2.5 mg orally prior to thrombolysis and 12 hours later
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 9579293

Group type: EXPERIMENTAL
Intervention: levodopa + apomorphine (1 mg/h)
Number of subjects: 10

Group type: COMPARATOR
Intervention: levodopa + saline (placebo)
Number of subjects: 10
Study: 7898706

Group type: EXPERIMENTAL
Intervention: Type A botulinum toxin
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Type F botulinum toxin
Number of subjects: 9
Study: 2347694

Group type: EXPERIMENTAL
Intervention: Center-based program with one education and two fitness sessions per week for 14 weeks; included individual counseling, small group education, aerobic activity, and snack components.
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (details not specified in the abstract).
Number of subjects: 94
Study: 434745

Group type: EXPERIMENTAL
Intervention: 8-0 Dexon 'S' polyglycolic acid sutures
Number of subjects: 30

Group type: COMPARATOR
Intervention: 8-0 Vicryl polyglactin sutures
Number of subjects: 30